MedTrace Logo

Treatment of Newly Diagnosed Peripheral T-cell Lymphoma

NCT03631862 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2018-08-15

No results posted yet for this study

Summary

The purpose of this study is to evaluate the efficacy and safety of Apatinib Combined With CHOP Regimen(cyclophosphamide, vincristine, epirubicin, prednisone in the treatment of newly diagnosed peripheral T-cell lymphoma.

Conditions

  • Newly Diagnosed Peripheral T-cell Lymphoma

Interventions

DRUG

Apatinib

Apatinib is an orally administrated small molecule receptor tyrosine kinase inhibitor selectively targeting VEGFR-2, showing anti-tumor activity across a broad range of advanced cancers.

DRUG

CHOP Regimen

CHOP regimen(Cyclophosphamide,Vindesine,Epirubicin,Prednisone)

Sponsors & Collaborators

  • Zhengzhou University

    lead OTHER

Principal Investigators

  • Mingzhi Zhang, Pro,Dr · China, Henan Oncology Department of The First Affiliated Hospital of Zhengzhou University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
14 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-09-01
Primary Completion
2019-12-31
Completion
2019-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03631862 on ClinicalTrials.gov